

Anne Harris
Managing Director



Pfizer Australia Pty Ltd
ABN: 50 008 422 348
L15-18, 151 Clarence Street
Sydney NSW 2000
Australia
Tel +61 2 9850 3333

8 May 2020

Australian Competition & Consumer Commission
23 Marcus Clarke Street
CANBERRA ACT 2601

Dear Mr Saunders

Re: Medicines Australia application for authorisation AA1000486 – request for update

Pfizer Australia welcomes the ACCC's interim authorisation for Medicines Australia, its members and the Generic and Biosimilar Medicines Association and its members, in relation to the supply of essential medicines and related supplies in response to the current COVID-19 pandemic.

Medicines Australia (MA) and the Generic and Biosimilar Medicines Association (GBMA) have issued clear guidance on the specific rules to help companies understand what is permitted when engaging with any other member of the MA/GBMA Working Group.

Pfizer has participated in one meeting of the MA/GBMA working group at this stage, where the authorisation enabled the working group to assess a potential disruption to the supply of a critical hospital medicine.

Pfizer believes the authorisation will assist suppliers to continue to make available the important medicines patients require.

Yours sincerely



Anne Harris
Managing Director - Pfizer Australia & New Zealand